Cash pulled forward: buyers are funding the company's next stage in advance, and the money keeps arriving
The model's full reasoning — Q4 2023 call → NOWe need to determine if the transcript shows that the company receives money or binding financial commitments ahead of the work it will pay for, and that this advance funding is growing and finances/de-risks the next stage. Key points from transcript: - CollPlant has a collaboration with AbbVie for dermal filler. They received a $10 million milestone payment in June 2023. This is a milestone payment, which is typically paid upon achieving a development milestone, not necessarily in advance of work. But it is a payment from a partner for achieving a milestone, which is a form of advance funding? Actually, milestone payments are often paid when a milestone is achieved, which is after some work is done. But the question is about money arriving ahead of the work it will pay for. The milestone payment is for achieving a milestone, so it's not necessarily ahead of delivery. However, the transcript says: "In June of last year, we announced the achievement of an important milestone under this collaboration, which triggered a $10 million payment from AbbVie to CollPlant." That is a payment for a milestone achieved, not an advance. Also, they mention potential additional milestones and royalties. But the question is about advance funding that is growing and finances next stage. The $10 million is a one-time payment, not described as growing. Also, they have a photocurable dermal filler product candidate, but they have granted AbbVie right of first negotiation, not a binding commitment. - They have a collaboration with Stratasys for bioprinting. That is a joint development agreement, not necessarily advance funding. - They have a gut-on-a-chip program that they put on hold. - They have cash and cash equivalents of $26.7 million, and they believe that will fund operations until end of 2025. That is from their own cash, not from advance payments. - They mention revenues from sales of rhCollagen products, but that is ordinary course. - They mention that they are eligible for up to an additional $226 million in milestone payments from AbbVie, but that is potential, not received.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
SYM · Q3 2022 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes a "very significant cost float" from "strong deferred revenue on the balance sheet" that helps fund the company's growth strategy, along with improved payable terms. This ties directly to the $11.3 billion backlog and the ability to invest aggressively in scaling deployments, inventory, and operations ahead of full revenue recognition.
IONS · Q1 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes exactly this pattern: Novartis delivered $175 million (including $75 million upfront plus $100 million equity at a premium) before the Phase IIb studies are conducted, and Bayer paid $75 million to advance IONIS-FXIRx and IONIS-FXI-LRx before full development work is complete 65-plus percent of which was already recognized in Q1.
LIND · Q2 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and if they treat this as growing and financ...YES The transcript shows management describing a clear pattern of advance bookings and forward reservations that are growing (nearly 40% year-to-date, up nearly 50% in July, highest booking day ever) and that directly de-risk and finance the next stage of growth.